nach oben

European Journal of Nuclear Medicine and Molecular Imaging

08.04.2024 | Editorial

Artificial intelligence-based application in multiple myeloma

verfasst von: Leandra Piscopo, Mariano Scaglione, Michele Klain

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging

Einloggen, um Zugang zu erhalten

Excerpt

Multiple myeloma (MM) is a hematological disease characterized by abnormal clonal proliferation of malignant plasma cells in the bone marrow (BM). Approximately, its estimated incidence is around 600,000 new cases per year worldwide, and the median 5-year survival of MM patients is about 82% [1]. …

Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464–77. https://doi.org/10.1001/jama.2022.0003.CrossRefPubMed

Caers J, Garderet L, Kortüm KM, O’Dwyer ME, van de Donk NWCJ, Binder M, et al. European myeloma network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica. 2018;103(11):1772–84. https://doi.org/10.3324/haematol.2018.189159.CrossRefPubMedPubMedCentral

Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–20. https://doi.org/10.1200/JCO.2005.04.242.CrossRefPubMed

D’Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(29):3406–18. https://doi.org/10.1200/JCO.21.02614.CrossRefPubMed

Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2019;133(7):660–75. https://doi.org/10.1182/blood-2018-09-825331.CrossRefPubMedPubMedCentral

Boussi LS, Avigan ZM, Rosenblatt J. Immunotherapy for the treatment of multiple myeloma. Front Immunol. 2022;28(13):1027385. https://doi.org/10.3389/fimmu.2022.1027385.CrossRef

Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of ¹⁸F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206–17. https://doi.org/10.1016/S1470-2045(17)30189-4.CrossRefPubMed

Zanoni L, Mattana F, Calabrò D, Paccagnella A, Broccoli A, Nanni C, Fanti S. Overview and recent advances in PET/CT imaging in lymphoma and multiple myeloma. Eur J Radiol. 2021;141: 109793. https://doi.org/10.1016/j.ejrad.2021.109793.CrossRefPubMed

Klain M, Maurea S, Gaudieri V, Zampella E, Volpe F, Manganelli M, et al. The diagnostic role of total-body 18F-FDG PET/CT in patients with multiple tumors: a report of the association of thyroid cancer with lung or renal tumors. Quant Imaging Med Surg. 2021;11(9):4211–5. https://doi.org/10.21037/qims-21-36.CrossRefPubMedPubMedCentral

10.

Ponsiglione A, Nappi C, Volpe F, Klain M. Expanding the long-axial field-of-view PET-CT horizons: unveiling new arrows in our quiver. Eur J Nucl Med Mol Imaging. 2024. https://doi.org/10.1007/s00259-024-06665-2.CrossRefPubMed

11.

Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, et al. Standardization of ¹⁸F-FDG-PET/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J Clin Oncol. 2021;39(2):116–25. https://doi.org/10.1200/JCO.20.00386.CrossRefPubMed

12.

Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, et al. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2018;45(5):712–719. https://doi.org/10.1007/s00259-017-3909-8.

13.

Sachpekidis C, Enqvist O, Ulén J, Kopp-Schneider A, Pan L, Jauch A, et al. Application of an artificial intelligence-based tool in [¹⁸F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma. Eur J Nucl Med Mol Imaging. 2023;50(12):3697–708. https://doi.org/10.1007/s00259-023-06339-5.CrossRefPubMedPubMedCentral

14.

Mannam P, Murali A, Gokulakrishnan P, Venkatachalapathy E, Venkata Sai PM. Radiomic analysis of positron-emission tomography and computed tomography images to differentiate between multiple myeloma and skeletal metastases. Indian J Nucl Med. 2022;37(3):217–226. https://doi.org/10.4103/ijnm.ijnm_111_21.

15.

Tagliafico AS, Dominietto A, Belgioia L, Campi C, Schenone D, Piana M. Quantitative imaging and radiomics in multiple myeloma: a potential opportunity? Medicina (Kaunas). 2021;57(2):94. https://doi.org/10.3390/medicina57020094.CrossRefPubMed

16.

Piscopo L, Zampella E, Klain M. [18F]FET PET/MR and machine learning in the evaluation of glioma. Eur J Nucl Med Mol Imaging. 2024;51(3):797–9. https://doi.org/10.1007/s00259-023-06505-9.CrossRefPubMed

17.

Stanzione A, Cuocolo R, Bombace C, Pesce I, Mainolfi CG, De Giorgi M, et al. Prediction of 2-[18F]FDG PET-CT SUVmax for adrenal mass characterization: a CT radiomics feasibility study. Cancers (Basel). 2023;15(13):3439. https://doi.org/10.3390/cancers15133439.CrossRefPubMed

18.

Fanni SC, Greco G, Rossi S, Aghakhanyan G, Masala S, Scaglione M, et al. Role of artificial intelligence in oncologic emergencies: a narrative review. Explor Target Antitumor Ther. 2023;4(2):344–54. https://doi.org/10.37349/etat.2023.00138.CrossRefPubMedPubMedCentral

19.

Gabelloni M, Faggioni L, Fusco R, Simonetti I, De Muzio F, Giacobbe G, et al. Radiomics in lung metastases: a systematic review. J Pers Med. 2023;13(2):225. https://doi.org/10.3390/jpm13020225.CrossRefPubMedPubMedCentral

Titel: Artificial intelligence-based application in multiple myeloma
verfasst von: Leandra Piscopo
Mariano Scaglione
Michele Klain
Publikationsdatum: 08.04.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-024-06711-z

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten